Look­ing to so­lid­i­fy semaglu­tide's reign over GLP-1, No­vo Nordisk posts key PhII win

No­vo Nordisk is one step clos­er to un­lock­ing a new semaglu­tide fran­chise — one it hopes can spur even bet­ter re­sults for peo­ple with type 2 di­a­betes.

The key­word here is Ca­griSe­ma, a sub­cu­ta­neous com­bi­na­tion of semaglu­tide and an ex­per­i­men­tal amylin ana­logue dubbed ca­gril­in­tide. In a Phase II study, the fixed-dose drug, ad­min­is­tered once week­ly, trig­gered “nu­mer­i­cal­ly high­er” re­duc­tions in blood sug­ar lev­els and body weight than ei­ther drug alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER